Medeon Biodesign, Inc. AI Stock Analysis
Medeon Biodesign, Inc. (6499) AI Stock Analysis
Medeon Biodesign, Inc.
(TPEx:6499)
The overall score is very low, driven primarily by a fundamentally broken financial model. The company's massive cash burn and collapsed profit margins present an existential risk, despite a low-debt balance sheet that provides a temporary cushion. Technical trends reinforce this weakness, with the stock in a clear downtrend and showing no signs of a momentum shift. The negative P/E ratio confirms the lack of earnings, making the stock highly speculative. The recent return to revenue growth is the only mitigating factor, but it is insufficient to offset the severe operational and market headwinds.
Medeon Biodesign, Inc. (6499) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 6.92B
- Dividend Yield
- ―
- Average Volume (3M)
- 373.34K
- Price to Earnings (P/E)
- -16.4
- Beta (1Y)
- 0.50
- Revenue Growth
- 69.62%
- EPS Growth
- 59.41%
- Country
- TW
- Employees
- 1,496
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Instruments & Supplies
Medeon Biodesign, Inc. Business Overview & Revenue Model
Company Description
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular clo...
Medeon Biodesign, Inc. Financial Statement Overview
Summary
Financial performance is severely constrained by deep and persistent operating losses. The collapse in gross margins to 14.0% TTM and an EBIT margin of -172.3% TTM indicate a fundamentally unprofitable operation. While the balance sheet is a relative strength with very low debt, the company is burning over $629 million in operating cash flow TTM, eroding its equity base. The recent revenue rebound is a positive signal, but it is overshadowed by the critical inability to translate sales into profit or cash.
Income Statement
18Very NegativeBalance Sheet
72PositiveCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 428.06M | 419.43M | 292.81M | 196.26M | 298.32M | 68.96M |
| Gross Profit | 39.23M | 58.83M | 83.41M | -65.20M | 186.81M | 28.63M |
| EBITDA | -540.29M | -615.15M | -754.42M | -1.14B | -370.10M | -453.87M |
| Net Income | -575.91M | -668.06M | -805.51M | -1.20B | -433.76M | 2.08B |
Balance Sheet | ||||||
| Total Assets | 1.55B | 1.78B | 1.88B | 2.75B | 4.04B | 4.36B |
| Cash, Cash Equivalents and Short-Term Investments | 959.51M | 1.22B | 1.21B | 2.14B | 1.55B | 2.35B |
| Total Debt | 151.49M | 113.05M | 168.40M | 186.74M | 198.91M | 30.24M |
| Total Liabilities | 282.14M | 243.03M | 341.84M | 375.65M | 376.48M | 176.00M |
| Stockholders Equity | 1.23B | 1.48B | 1.52B | 2.32B | 3.60B | 4.13B |
Cash Flow | ||||||
| Free Cash Flow | -520.83M | -645.56M | -907.44M | -810.36M | -602.06M | -302.39M |
| Operating Cash Flow | -511.73M | -629.09M | -832.66M | -755.08M | -461.34M | -293.38M |
| Investing Cash Flow | -118.74M | 272.56M | 135.21M | 1.60B | 263.44M | -90.64M |
| Financing Cash Flow | 374.49M | 373.88M | -46.68M | -90.57M | -101.16M | -3.90M |
Medeon Biodesign, Inc. Peers Comparison
Overall Rating
TW:410778Outperform
TW:412968Neutral
TW:416359Neutral- TW:649942.5Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4107 | 78Outperform | TWD 7.35B | 12.29 | ― | 5.12% | 10.16% | 17.15% |
| TW:4129 | 68Neutral | TWD 7.01B | 12.73 | ― | 6.19% | 18.91% | 10.75% |
| TW:4163 | 59Neutral | TWD 6.41B | 20.66 | ― | 2.78% | 4.16% | 40.82% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6499 | 43Neutral | TWD 7.33B | -16.44 | ― | ― | 69.62% | 59.41% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6499 | Medeon Biodesign, Inc. | 72.40 | -24.10 | -24.97% | |
| TW:4107 | Bioteque Corporation | 106.00 | -15.63 | -12.85% | |
| TW:4129 | United Orthopedic Corporation | 72.70 | -43.31 | -37.33% | |
| TW:4163 | Intai Technology Corp. | 126.00 | 30.50 | 31.94% | |
| TW:6891 | Locus Cell Co., Ltd. | 36.85 | 7.05 | 23.66% | |
| TW:6907 | Artery Technology Corporation | 120.00 | 71.34 | 146.63% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026